Clinical trials
Premenopausal Breast Cancer clinical trials
Below are recruiting premenopausal breast cancer clinical trials, each written for real people, not researchers. We’re tracking 126 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04646759RecruitingPhase 3
Fulvestrant or capecitabine plus pyrotinib for metastatic breast cancer
This Phase 3 trial tests adding pyrotinib to standard hormone-based treatments (fulvestrant or capecitabine) to slow or control metastatic breast cancer. It’s for tumors that are hormone-receptor positive and HER2 positive, where standard options have been used before.
Guangzhou, GuangdongAges 18–80 - NCT02535221RecruitingPhase 3
Hormone treatment vs chemotherapy before breast surgery
This Phase 3 trial compares hormone-based treatment versus chemotherapy given before surgery in people who are premenopausal and have hormone-receptor positive, HER2-negative breast cancer. It looks to see which approach works better to control the cancer before the breast operation.
BeijingAges 35–55 - NCT05305092Recruiting
Study of memory and thinking in early breast cancer
This study checks how breast cancer affects memory and thinking before other treatments start. It may help doctors better understand cognitive changes and who is most at risk.
Xi'an, ShaanxiAges Any age - NCT05638594RecruitingPhase 2
Neoadjuvant drug study for hormone- and HER2-positive breast cancer
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
Shenyang, LiaoningAges 18–75 - NCT05720260RecruitingPhase 2
Test immunotherapy plus hormone therapy and an AKT blocker
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
TaipeiAges 20 years+ - NCT07708194RecruitingPhase 1/Phase 2
Entinostat plus pyrotinib and hormone therapy for advanced breast cancer
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07678957RecruitingPhase 2
Comparing BL-M07D1 vs DS-8201 for HR-positive, HER2-low breast cancer
This trial compares a new drug, BL-M07D1, to an existing treatment (DS-8201) for women with HR-positive, HER2-low breast cancer that has come back or spread. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07671885RecruitingPhase 3
Hormone therapy before surgery for premenopausal breast cancer
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
AkitaAges 18 years+ - NCT05063136RecruitingPhase 3
Metronomic capecitabine with hormone therapy after breast cancer
This trial studies whether a low-dose “metronomic” chemotherapy medicine (capecitabine) added to standard hormone therapy can reduce breast cancer coming back. It is for people with hormone-receptor–positive, HER2-negative breast cancer after surgery and chemo.
Zhengzhou, HenanAges 18–70 - NCT07502820RecruitingPhase 3
Personalized tamoxifen dosing for breast cancer
This trial tests whether adjusting the dose of tamoxifen based on your body's processing can improve treatment for hormone-sensitive breast cancer. It aims to find the best dose for you while keeping side effects manageable.
BoråsAges 18 years+ - NCT07492394RecruitingPhase 2
Testing dalpiciclib with or without entinostat and letrozole for early breast cancer
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
Shijiazhuang, HebeiAges 18–75 - NCT07482384Recruiting
Support program for young women with early-stage breast cancer
This study tests a mobile health program that provides support and information to young women with early-stage breast cancer who are on hormone therapy. The goal is to help you stay on your treatment and manage side effects.
Boston, MassachusettsAges 18–49 - NCT07460752RecruitingPhase 2
Alternative injection site for goserelin in breast cancer patients
This trial is testing whether giving the drug goserelin in a different spot on the body works just as well for suppressing ovarian function in premenopausal women with hormone receptor positive breast cancer. You may be a fit if you've already been on goserelin shots in your abdomen for at least 6 months.
Rochester, MinnesotaAges 18–50 - NCT07439458Recruiting
Exercise effects on tumor cells in breast cancer survivors
This trial tests whether different types and intensities of exercise can change tumor-related cells in survivors of triple-negative breast cancer. It may help understand how exercise could improve long-term outcomes.
Riga, Dzirciema Street 16Ages 35 years+ - NCT07349069RecruitingPhase 3
HRS-8080 vs. standard hormone therapy for early breast cancer
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
Nanjing, JiangsuAges 18–75 - NCT07310420RecruitingPhase 1
Evaluating ovarian suppression with ZOLADEX in premenopausal breast cancer
This trial tests a medication (ZOLADEX) to suppress ovarian function in premenopausal women with hormone receptor-positive breast cancer, either early-stage or advanced. The goal is to see how well it works and how safe it is.
Hot Springs, ArkansasAges 18–55 - NCT07274852RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
Chengdu, SichuanAges 18 years+ - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT06313983RecruitingPhase 3
Study of hemay022 plus hormone therapy for advanced breast cancer
This trial tests a new targeted drug (hemay022) combined with an aromatase inhibitor (a type of hormone therapy) for people with advanced breast cancer that is both hormone-receptor-positive and HER2-positive. It may be an option if you've already tried trastuzumab or a similar treatment and it stopped working.
BeijingAges 18 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT06225284RecruitingPhase 2
Chemotherapy with or without hormone drug for premenopausal TNBC
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
TaipeiAges 18 years+ - NCT07159451RecruitingPhase 2
Elacestrant for premenopausal women with early breast cancer
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
VillejuifAges 18 years+ - NCT03144648Recruiting
Study of breast cancer subtypes in premenopausal women in Latin America
This study looks at different biological “subtypes” of breast cancer in women who are still having periods. It helps researchers understand the cancer type and may guide more personalized care in the future.
BarretosAges 20–45
Hear when a new Premenopausal Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for premenopausal breast cancer?
- Yes. Clin2 currently lists 126 recruiting premenopausal breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a premenopausal breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a premenopausal breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.